Skip to main content
SpringerLink
Log in

Global Healthcare Financing for Type II Diabetes

Are There Ways Out of the Crisis?

  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

This article focuses on the overall situation with regard to healthcare financing in the field of diabetes. Worldwide efforts on cost containment have severely influenced the management of chronic illness. An answer as to whether or not the expected financial crisis can be prevented will be difficult to obtain. However, use of the modern tools of management sciences and health economics can bring more transparency into the picture. Solutions will have to be based increasingly on empirical economic data, which, so far, are only in the process of being generated in many countries. A research agenda is proposed that might trigger the compilation of additional data in order to ensure adequate future financing of diabetes care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clark CM, Lee DA. Drug therapy: prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210–7

    Article  PubMed  Google Scholar 

  2. Jönsson B. Diabetes — The cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand 1983; 671: 19–27

    Google Scholar 

  3. Leese B. The cost of diabetes and its complications: a review. Discussion Paper 1991; University of York: No. 94

  4. Huse DM, Oster G, Killen AR, et al. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989; 262 (19): 2708–13

    Article  PubMed  CAS  Google Scholar 

  5. Donaldson C, Gerard K. Economics of health care financing. The visible hand. London: 1993

  6. The DCCT Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86

    Article  Google Scholar 

  7. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62

    Article  PubMed  CAS  Google Scholar 

  8. Cook DJ, Guyatt GH, Laupacis A, et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102 Suppl. 4.: 30S-11S

    Article  CAS  Google Scholar 

  9. Chalmers TC, Hewett P, Reitman D, et al. Selection and evaluation of empirical research in technology. Int J Technol Ass Healthcare 1989; 5: 521–36

    Article  CAS  Google Scholar 

  10. O’Meara JJ, McNutt RA, Evans AT, et al. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep vein thrombosis. N Engl J Med 1994; 330 (26): 1895–6

    Article  Google Scholar 

  11. Kassirer JP. Incorporating patients’ preferences into medical decisions [editorial; comment]. N EnglJ Med 1994; 330 (26): 1864–9

    Article  Google Scholar 

  12. Torrance G, Furlong W, Feeny D. Multi-attribute preference functions: health utilities index. PharmacoEconomics 1995; 7 (6): 503–20

    Article  PubMed  CAS  Google Scholar 

  13. Hilborne LH, Leape LL, Bernstein SJ, et al. The appropriateness of use of percutaneous transluminal coronary angioplasty in New York State. JAMA 1993; 269 (6): 761–5

    Article  PubMed  CAS  Google Scholar 

  14. Manning WJ, Newhouse JP, Guon N, et al. Health insurance and the demand for medical care: evidence from a randomised experiment. Am Econ Rev 1987; 77 (3): 251–77

    PubMed  CAS  Google Scholar 

  15. Bernstein SJ, Hilborne LH, Leape LL, et al. The appropriateness of use of coronary angiography in New York State. JAMA 1993; 269 (6): 766–9

    Article  PubMed  CAS  Google Scholar 

  16. Jönsson B. Diabetes — the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand Suppl. 1983; 671: 19–27

    PubMed  Google Scholar 

  17. Olivera EM, Duhalde EP, Gagliordino JJ. Costs of temporary and permanent disability induced by diabetes. Diabetes Care 1991; 14: 593–6

    Article  PubMed  CAS  Google Scholar 

  18. Detsky AS, Naglie IG. A clinicians guide to cost effectiveness analysis. Ann Intern Med 1990; 113: 147–54

    PubMed  CAS  Google Scholar 

  19. Effects of limiting Medicaid reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331: 650–5

    Google Scholar 

  20. Eddy DM. Designing a practice policy — standards, guidelines and options. JAMA 1990; 263 (22): 3077–84

    Article  PubMed  CAS  Google Scholar 

  21. Eddy DM. Guidelines for policy statements: the explicit approach. JAMA 1990; 263 (16): 2239–43

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Economics Research Group and Department of Internal Medicine, Ludwig Maximilian’s University, Steinstrasse 56, D-81667, München, Germany

    Thomas D. Szucs

Authors
  1. Thomas D. Szucs
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szucs, T.D. Global Healthcare Financing for Type II Diabetes. Pharmacoeconomics 8 (Suppl 1), 62–67 (1995). https://doi.org/10.2165/00019053-199500081-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199500081-00014

Keywords

Search

Navigation